Login / Signup
Marc Pfeffer presented the results of PARADISE-MI at ACC last week. As discussed previously on CVCTCardiobrief, sacubitril/valsartan did not reduce the primary outcome compared to…
New Guidelines for Endpoints in Valve Intervention Trials: is it an autocracy?
“History has time and again shown that unlimited power in the hands of one person or group in most cases means that others are suppressed…
What Happened to Hospital Attendance: A Perception Trap
Hospital admissions for almost everything came to almost a complete halt this year because of the pandemic. In March and April 2020, people stopped coming…
Missed MI in the emergency department and early stress testing
People with chest pain go to the Emergency Department (ED). They get checked out. Some get diagnosed with acute coronary syndrome. Some get diagnosed with other conditions. And some get told there is nothing wrong.
Surviving A Heart Attack: Location And Time Make A Big Difference
Two studies published this week offer fresh evidence that your life may depend on where and when you have a heart attack. 1. Heart attack patients…
Stents Lose In Comparisons With Surgery And Medical Therapy
Despite the enormous increase in the use of stents in recent decades, there is little or no good evidence comparing their use to the alternatives…
Little Difference In Chest Pain Between Men And Women
In recent years the medical community has grown increasingly concerned that women with heart attacks may be less likely to receive prompt and effective treatment.…
FDA Removes Restrictions On Avandia
In a remarkable climax to a long-running drama, the FDA today lifted major restrictions on rosiglitazone (Avandia, GlaxoSmithKline). The drug has been the subject of intense criticism and controversy…
Promising GSK Heart Drug Misses Primary Endpoint In 15,000 Patient Trial
GlaxoSmithKline announced today that the first of two large pivotal phase 3 trials with a new drug, darapladib, had failed to meet its primary endpoint. Full…
Should You Be Worried About The Treatment For Low-T?
The ubiquitous ads ask: “Should I be worried about Low-T”? But now there’s a good chance there’s a more important question: “Should I be worried…